Howard Hochster, MD, on whether atezolizumab + bevacizumab regimen is a new standard in care in HCC

Dr. Hochster, Distinguished Professor of Medicine, Rutgers Cancer Institute, on whether Tecentriq (atezolizumab) + Avastin (bevacizumab) regimen is a new standard in care in the management of HCC and thoughts on if a patient begins to progress on this regimen